Willow and Enterin Collaborate to Develop Sustainable Intermediates and Active Pharmaceutical Ingredients (APIs)
Wednesday, January 17, 2024
Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology firm focused on advancing the industrial production of pure, consistent, and sustainable ingredients, has revealed a collaborative effort with Enterin, Inc. This clinical stage biopharmaceutical company specializes in pioneering novel treatments for neurodegenerative and metabolic disorders. The collaboration's objective is to devise new, sustainable manufacturing processes for crucial intermediates and active pharmaceutical ingredients (APIs).
Recognizing the imperative for sustainable and cost-effective manufacturing methods with reduced waste, Enterin has sought Willow's expertise in developing and scaling biobased processes. The initial program will assess the viability of establishing a biobased pathway, and successful outcomes could pave the way for the implementation of the process on a commercial scale. The development phase of this funded collaboration is anticipated to span approximately three months.
Expressing enthusiasm about being selected by Enterin for this collaboration, Dr. Chris Savile, Willow's President & CEO, highlighted the application of their AI-enabled technology platform in developing sustainably sourced intermediates and APIs. The objective is to create a biobased route that is not only more sustainable but also cost-effective, ensuring access to the potentially life-changing medicines in Enterin's development pipeline.
This agreement marks Willow's third development collaboration with innovator/discovery food or pharmaceutical companies, illustrating the demand for access to Willow's transformative BioOxiTM selective hydroxylation platform.
Source: prnewswire.com
